Prosecution Insights
Last updated: April 19, 2026

Examiner: MCDOWELL, BRIAN E

Tech Center 1600 • Art Units: 1624

This examiner grants 74% of resolved cases

Performance Statistics

74.2%
Allow Rate
+14.2% vs TC avg
1160
Total Applications
+30.3%
Interview Lift
852
Avg Prosecution Days
Based on 1102 resolved cases, 2023–2026

Rejection Statute Breakdown

1.0%
§101 Eligibility
19.5%
§102 Novelty
15.0%
§103 Obviousness
47.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18117966 NOVEL HETEROCYCLIC COMPOUNDS Non-Final OA Hoffmann-La Roche Inc.
17869755 NOVEL HETEROCYCLIC COMPOUNDS Non-Final OA Hoffmann-La Roche Inc.
17997013 Small Molecule Inhibitors That Block the Budding of Enveloped Viruses Non-Final OA Northwestern University
17552413 CARBONIC ANHYDRASE INHIBITORS FOR TREATMENT OF NEISSERIA GONORRHOEAE INFECTION Final Rejection Purdue Research Foundation
19235393 MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS Non-Final OA Neumora Therapeutics, Inc.
16948467 TLR7/8 ANTAGONISTS AND USES THEREOF Non-Final OA Merck Patent GmbH
18337476 N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES Non-Final OA AstraZeneca AB
18639608 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF Final Rejection REGENTS OF THE UNIVERSITY OF MINNESOTA
18322445 SMALL MOLECULE DEGRADERS OF THE BROMODOMAIN AND PHD FINGER TRANSCRIPTION FACTOR Non-Final OA Regents of the University of Minnesota
18253726 COMPOUNDS AS PU. 1 INHIBITORS Non-Final OA Peking University
17308555 ARTICLE INCLUDING PHTHALOCYANINE DYES Final Rejection VIAVI SOLUTIONS INC.
17638383 TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND INFLAMMATORY STEATOHEPATITIS WITH SLC25A1 INHIBITORS Final Rejection GEORGETOWN UNIVERSITY
17296665 HALOGENATED ZINC PHTHALOCYANINE PIGMENT AND PRODUCTION METHOD THEREFOR Non-Final OA DIC Corporation
18468885 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS Non-Final OA Boehringer Ingelheim International GmbH
17016158 METHOD AND COMPOSITION FOR ADMINISTERING PROSTAGLANDINS Non-Final OA MannKind Corporation
17799639 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Final Rejection SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
18271523 NOVEL BENZOAZEPINE COMPOUND, AND COMPOSITION AND USE THEREOF Non-Final OA SHANGHAITECH UNIVERSITY
18021760 A PRECIPITATION PROCESS FOR AMORPHOUS LETERMOVIR Non-Final OA Lupin Limited
17277829 STEROL ANALOGS AND USES THEREOF Final Rejection ModernaTX, Inc.
18434994 Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase Final Rejection Kadmon Corporation, LLC
18414198 MORPHIC FORMS OF HEXADECYLOXYPROPYL-PHOSPHONATE ESTERS AND METHODS OF SYNTHESIS THEREOF Non-Final OA EMERGENT BIODEFENSE OPERATIONS LANSING LLC
18577856 NEW SELECTIVE ANGIOTENSIN II COMPOUNDS Non-Final OA VICORE PHARMA AB
17793297 NON-PERIPHERAL QUATERNARY AMMONIUM-MODIFIED ZINC PHTHALOCYANINE AND PREPARATION METHOD AND USE THEREOF Non-Final OA FUZHOU UNIVERSITY
17499048 DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES Final Rejection UNIVERSITÄT BASEL
18230392 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG Final Rejection Shionogi & Co., Ltd.
17920583 H4 ANTAGONIST COMPOUNDS Final Rejection NXERA PHARMA UK LIMITED
18036549 KINASE MODULATORS AND METHODS OF USE THEREOF Non-Final OA NEURON23, INC.
18461179 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Final Rejection Pardes Biosciences, Inc.
17779522 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Final Rejection SHANGHAI KUNHENG PHARMA-TECH CO., LTD
18334608 RIP1 Inhibitory Compounds and Methods for Making and Using the Same Non-Final OA Rigel Pharmaceuticals, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month